Search research articles
Contact Us
Filters
Showing results (1-10 of 66) with videos related to
Page
of 7
Sort By:
Current Clinical Pharmacology
|
August 12, 2008
The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease
Soo-Peang Khor, Ann Hsu
Neuropharmacology
|
March 5, 2004
The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons
Kurt Rasmussen, Mei-Ann Hsu, Jim Vandergriff
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
October 26, 2006
The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy
Kurt Rasmussen, Mei-Ann Hsu, Yili Yang
Cancer Journal (Sudbury, Mass.)
|
October 15, 2009
Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance
Peter C Trask, Ming-Ann Hsu, Richard McQuellon
Journal of Clinical Pharmacology
|
February 22, 2013
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease
Zhongping Mao, Ann Hsu, Suneel Gupta, et al.
Journal of Clinical Pharmacology
|
April 10, 2015
Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®))
Ann Hsu, Hsuan-Ming Yao, Suneel Gupta, et al.
Clinical Neuropharmacology
|
December 3, 2015
Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers
Hsuan-Ming Yao, Ann Hsu, Suneel Gupta, et al.
International Journal of Women'S Health
|
June 6, 2013
Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom
Marco Dacosta Dibonaventura, Arthi Chandran, Ming-Ann Hsu, et al.
Archives of Otolaryngology--Head & Neck Surgery
|
November 17, 2004
The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data
Kathleen Lang, Joseph Menzin, Craig C Earle, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 16, 2008
Psychometric validation of the cancer therapy satisfaction questionnaire
Peter C Trask, Crystal Tellefsen, Derek Espindle, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 66) with videos related to
Sort By:
Page
of 7
Current Clinical Pharmacology
|
August 12, 2008
The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease
Soo-Peang Khor, Ann Hsu
Neuropharmacology
|
March 5, 2004
The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons
Kurt Rasmussen, Mei-Ann Hsu, Jim Vandergriff
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
October 26, 2006
The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy
Kurt Rasmussen, Mei-Ann Hsu, Yili Yang
Cancer Journal (Sudbury, Mass.)
|
October 15, 2009
Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance
Peter C Trask, Ming-Ann Hsu, Richard McQuellon
Journal of Clinical Pharmacology
|
February 22, 2013
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease
Zhongping Mao, Ann Hsu, Suneel Gupta, et al.
Journal of Clinical Pharmacology
|
April 10, 2015
Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®))
Ann Hsu, Hsuan-Ming Yao, Suneel Gupta, et al.
Clinical Neuropharmacology
|
December 3, 2015
Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers
Hsuan-Ming Yao, Ann Hsu, Suneel Gupta, et al.
International Journal of Women'S Health
|
June 6, 2013
Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom
Marco Dacosta Dibonaventura, Arthi Chandran, Ming-Ann Hsu, et al.
Archives of Otolaryngology--Head & Neck Surgery
|
November 17, 2004
The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data
Kathleen Lang, Joseph Menzin, Craig C Earle, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 16, 2008
Psychometric validation of the cancer therapy satisfaction questionnaire
Peter C Trask, Crystal Tellefsen, Derek Espindle, et al.
Page
of 7